Hepatocellular Carcinoma |
C3H |
|
++ |
Hca-F (HCa/16A3-F) |
World J. Gastroenterol. 2004 Feb 15;10(4):521-4 Carcinogenesis 2005 Mar;26(3):513-23
|
Mammary Adenocarcinoma |
FVB |
|
+ |
DB-7(fvb2) |
Clin. Exp. Metastasis 2005;22(1):47-59
|
Melanoma |
DBA/2 |
|
|
Cloudman S91 (Clone M-3) |
Int. J. Radiat. Oncol. Biol. Phys. 1987 Nov;13(11):1725-33 Prostaglandins 1983 Sep;26(3):449-56 Mol. Ther. 2003 Apr;7(4):498-505 Br. J. Cancer 1988 Jan;57(1):64-9
|
Lymphoma |
Black 6 (B6NTac) |
|
|
C6VL |
J. Immunol. 2004 Jan 15;172(2):929-36 J. Immunol. 1982 Nov;129(5):2293-300
|
Fibrosarcoma |
Black 6 (B6NTac) |
|
|
MC57G |
J. Immunol. 2004 Jan 15;172(2):929-36
|
Melanoma |
Black 6 (B6NTac) |
-- |
++ |
B16F10 |
Cancer Res. 1975 Jan;35(1):218-24 Cancer Res. 1999 Aug 15;59(16):4035-41 Nat. Med. 2016 Dec;22(12):1402-1410 Cancer Cell Int. 2013;13:75 Nature 2015 May 07;521(7550):99-104 Life Sci. 2002 Jan 04;70(7):791-8 Mol. Ther. 2003 Apr;7(4):498-505 PLoS ONE 2013;8(6):e66081
|
Hepatoma |
C3H |
|
++ |
Hepatoma 134 (MH-134) |
Cancer Res. 1985 Apr;45(4):1532-5
|
Lymphosarcoma |
C3H |
|
|
6C3HED |
Cancer Res. 1998 Jun 15;58(12):2594-600
|
Leukemia |
Black 6 (B6NTac) |
- |
|
RBL-5 |
J. Immunol. 1976 Oct;117(4):1267-74 J. Natl. Cancer Inst. 1978 Jan;60(1):239-42 J. Natl. Cancer Inst. 1977 Jun;58(6):1661-4
|
Lung Squamous Cell Carcinoma |
DBA/2 |
|
+++ |
KLN205 |
Cancer Res. 1978 Jul;38(7):2084-90 Cell Rep 2016 May 17;15(7):1505-13 Clin. Cancer Res. 2004 Jan 01;10(1 Pt 1):293-300 In Vitro 1980 Oct;16(10):884-92
|
Mammary Adenocarcinoma |
BALB/c |
--- |
|
SM1 |
Proc. Natl. Acad. Sci. U.S.A. 1998 Aug 18;95(17):10067-71 Cancer Res. 1992 Oct 15;52(20):5732-7
|
Bladder Carcinoma |
C3H |
+ |
|
MBT-2 |
Urol. Res. 1997;25(3):179-82 Cancer Res. 1977 Aug;37(8 Pt 2):2918-29
|
Lymphoma |
BALB/c |
|
|
A20 (A-20) |
Blood 2009 Nov 12;114(20):4477-85 Adv Hematol 2012;2012:701704 Blood 2010 Jul 15;116(2):226-38 J. Immunol. 1979 Feb;122(2):549-54
|
Sarcoma |
BALB/c |
- |
|
Meth A Sarcoma (METH-A) |
Cell Prolif. 2001 Aug;34(4):211-22 Cell Prolif. 2003 Apr;36(2):87-100 Mol. Cell. Biol. 1989 Aug;9(8):3385-92 Proc. Natl. Acad. Sci. U.S.A. 1995 Mar 14;92(6):2219-23
|
Mammary Adenocarcinoma |
BALB/c |
|
+++ |
LM3 |
Carcinogenesis 2005 Mar;26(3):513-23 Int. J. Oncol. 1997 Sep;11(3):489-96
|
Lymphoma |
Black 6 (B6NTac) |
|
|
EL-4 |
Science 1971 Jan 08;171(3966):75-7 J. Immunol. 2004 Jan 15;172(2):929-36 J. Immunol. 2011 Apr 15;186(8):5004-11 Br. J. Cancer 1950 Dec;4(4):372-9
|
Prostate Adenocarcinoma |
Black 6 (B6NTac) |
|
|
TRAMP-C1D |
J. Biol. Chem. 2001 Apr 06;276(14):11204-13 Cancer Res. 1997 Aug 15;57(16):3325-30
|
Lymphosarcoma |
BALB/c |
|
|
LSTRA |
Leuk. Res. 2003 Apr;27(4):351-7 Cancer Res. 1968 Mar;28(3):434-9 EMBO J. 1982;1(12):1579-82 J. Immunol. 1976 Oct;117(4):1267-74 Mol. Cell. Biol. 1984 Dec;4(12):2705-13
|
Mammary Adenocarcinoma |
FVB |
|
|
H6O5 |
Oncogene 2012 May 24;31(21):2614-26 Proteomics 2010 Nov;10(21):3800-10
|
Plasmacytoma |
BALB/c |
|
|
J558 |
J. Exp. Med. 2001 Nov 05;194(9):1339-48
|
Lung Carcinoma |
Black 6 (B6NTac) |
|
+++ |
D122 (3LLD122) |
Int. J. Cancer 1984 Oct 15;34(4):567-73 Cancer Res. 1999 Aug 15;59(16):4035-41
|
Ovarian Carcinoma |
Black 6 (B6NTac) |
|
|
MOVCAR 5612 |
J Ovarian Res 2010 Oct 19;3:24 J. Biol. Chem. 2012 Aug 24;287(35):29873-86
|
Mammary Adenocarcinoma |
BALB/c |
|
|
D2F2 |
J. Leukoc. Biol. 1985 Nov;38(5):573-85 Br. J. Cancer 1992 May;65(5):641-8 Cancer Res. 2010 Oct 01;70(19):7431-41 Cancer Gene Ther. 2012 Apr;19(4):282-91
|
Ovarian Carcinoma |
Black 6 (B6NTac) |
|
|
MOVCAR 5447 |
J. Biol. Chem. 2012 Aug 24;287(35):29873-86 J Ovarian Res 2010 Oct 19;3:24
|
Colon Adenocarcinoma |
Black 6 (B6NTac) |
|
++ |
MC-38 |
Carcinogenesis 2005 Mar;26(3):513-23 Cancer Res. 1975 Sep;35(9):2434-9 Clin. Exp. Immunol. 2009 Jul;157(1):128-38 Nat Commun 2017 Feb 21;8:14572 J. Natl. Cancer Inst. 1976 Apr;56(4):871-3 PLoS ONE 2016;11(9):e0161779 J. Immunother. 2010 Sep;33(7):697-705
|
Lymphoid Leukemia |
DBA/2 |
+ |
|
L1210 |
J. Immunol. 2006 Jul 01;177(1):162-8 Immunology 2009 Sep;128(1 Suppl):e641-51 J. Natl. Cancer Inst. 1966 Mar;36(3):405-13, 415-21
|
Fibrosarcoma |
DBA/2 |
|
|
SaD2 |
J. Immunol. 1978 Sep;121(3):1007-9
|
Mammary Adenocarcinoma |
BALB/c |
|
|
TUBO |
J. Immunol. 2000 Nov 01;165(9):5133-42 Mol. Ther. 2013 Jan;21(1):91-100
|
Sarcoma |
129S6 |
++ |
|
F244 |
Immunology 2013 Jun;139(2):265-74 Cancer Immunol Res 2017 Feb;5(2):106-117 Oncoimmunology 2013 Jun 01;2(6):e24786
|
Lymphosarcoma |
BALB/c |
|
|
P1798 |
Mol. Cell. Endocrinol. 1980 Feb;17(2):95-102
|
Pancreatic Ductal Adenocarcinoma |
Black 6 (B6NTac) |
|
|
6606PDA |
Eur Surg Res 2011;47(2):98-107 Cell Biosci 2015;5:51 BMC Cancer 2011 Jan 28;11:40
|
Reticulum Cell Sarcoma |
Black 6 (B6NTac) |
|
|
M5076 (M5) |
Eur. J. Cancer 1996 Oct;32A(11):2011-8 Cancer Res. 1981 Apr;41(4):1271-80
|
Plasmacytoma |
BALB/c |
|
++ |
J558 |
Nat Commun 2017 Feb 21;8:14572 J. Natl. Cancer Inst. 1972 Sep;49(3):735-49 Carcinogenesis 2005 Mar;26(3):513-23
|
Prostate Adenocarcinoma |
Black 6 (B6NTac) |
|
|
TRAMP-C2 |
Cancer Res. 1997 Aug 15;57(16):3325-30
|
Mammary Adenocarcinoma |
DBA/2 |
+ |
+ |
T1699 |
Int. J. Cancer 1984 Jan 15;33(1):73-7
|
Lymphocytic Leukemia |
DBA/2 |
|
|
P1534 |
Int. Arch. Allergy Appl. Immunol. 1969;35(1):20-34
|
Glioma |
Black 6 (B6NTac) |
+++ |
|
GL261 (Glioma 261) |
Cancer Immunol. Immunother. 2015 Apr;64(4):447-57 Cancer Sci. 2006 Jun;97(6):546-53 PLoS ONE 2015;10(3):e0121314
|
Mammary Adenocarcinoma |
BALB/c |
|
++ |
D2.0R |
Carcinogenesis 2005 Mar;26(3):513-23 Clin. Exp. Metastasis 1993 Jan;11(1):103-12
|
Mammary Adenocarcinoma |
C3H |
|
|
C3HBA |
Eur J Cancer 1975 Dec;11(12):891-901
|
Gastric Adenocarcinoma |
Black 6 (B6NTac) |
|
|
mGC8 |
BMC Cancer 2006 Mar 14;6:57
|
Leukemia |
C3H |
-- |
|
DA1-3b |
Leuk. Res. 1999 Apr;23(4):415-6 Blood 2004 Oct 01;104(7):2124-33 Gene Ther. 2000 Aug;7(15):1312-6
|
Lung Carcinoma |
Black 6 (B6NTac) |
|
+++ |
LL/2 |
Carcinogenesis 2005 Mar;26(3):513-23 Cancer Lett. 1980 Nov;11(1):63-73
|
Mesothelioma |
BALB/c |
|
|
AB12 |
Int. J. Cancer 1992 Dec 02;52(6):881-6 Oncol. Rep. 2012 Aug;28(2):707-13 Mol. Ther. 2002 Aug;6(2):210-8
|
Erythroleukemia |
Black 6 (B6NTac) |
|
|
FBL-3 |
J. Immunol. 1976 Oct;117(4):1267-74 J. Natl. Cancer Inst. 1978 Jan;60(1):239-42 Cancer Res. 1968 Mar;28(3):434-9
|
Lymphoma |
Black 6 (B6NTac) |
|
|
E.G7-OVA |
Cell 1988 Sep 09;54(6):777-85 J. Immunol. 2011 Apr 15;186(8):5004-11
|
Lung Carcinoma |
BALB/c |
|
|
ASB-XIV |
Cancer Treat Rep 1983 Dec;67(12):1061-5 Cancer Immunol Res 2015 Dec;3(12):1333-43
|
Hepatoma |
C3H |
+ |
|
Hepatoma 134 (MH-134) |
J. Natl. Cancer Inst. 1981 Oct;67(4):947-56 Proc. Natl. Acad. Sci. U.S.A. 2004 Apr 06;101(14):4990-5
|
Mammary Adenocarcinoma |
FVB |
|
+++ |
Met-1(fvb2) |
Clin. Exp. Metastasis 2005;22(1):47-59
|
Lung Carcinoma |
Black 6 (B6NTac) |
|
++ |
3LL |
Cancer Lett. 1980 Nov;11(1):63-73 Blood 2010 Feb 18;115(7):1461-71 Clin. Cancer Res. 2007 Sep 15;13(18 Pt 1):5455-62 Cancer Res. 1999 Aug 15;59(16):4035-41
|
Osteosarcoma |
BALB/c |
|
+++ |
K7M2 |
Carcinogenesis 2005 Mar;26(3):513-23 Clin. Exp. Metastasis 2000;18(3):261-71
|
Ovarian Carcinoma |
Black 6 (B6NTac) |
|
|
ID8 (MOSEC) |
Anticancer Res. 26(4B):2785-9 Carcinogenesis 2000 Apr;21(4):585-91 J. Immunol. 2014 Nov 15;193(10):5327-37 Gynecol. Oncol. 2016 Aug;142(2):332-40 Gynecol. Oncol. 2008 Feb;108(2):385-94
|
Leukemia |
Black 6 (B6NTac) |
++ |
|
RMA (RBL-5 subclone) |
Nature 2015 May 07;521(7550):99-104 J. Immunol. 2014 Feb 15;192(4):1577-86 J. Exp. Med. 1985 Dec 01;162(6):1745-59
|
Testicular Carcinoma |
Black 6 (B6NTac) |
|
|
M5480 |
J. Natl. Cancer Inst. 1975 Sep;55(3):623-31
|
Leukemia |
DBA/2 |
|
|
L-5178-Y |
J. Immunol. 2009 Feb 15;182(4):1940-53 Mutat. Res. 2017 Feb;814:1-6 Proc. Natl. Acad. Sci. U.S.A. 1996 Jun 25;93(13):6291-6 J. Immunol. 2004 Jul 15;173(2):1012-22
|
Colon Adenocarcinoma |
Black 6 (B6NTac) |
|
|
MC-38-CEA-1 |
Cancer Res. 1991 Jul 15;51(14):3657-62
|
Ovarian Carcinoma |
Black 6 (B6NTac) |
|
|
MOVCAR 5009 |
J Ovarian Res 2010 Oct 19;3:24 J. Biol. Chem. 2012 Aug 24;287(35):29873-86
|
Plasmacytoma |
C3H |
|
|
C1.18.4 (C1-18) |
Exp. Cell Res. 1970 Apr;60(1):61-77
|
Gastric Adenocarcinoma |
Black 6 (B6NTac) |
- |
|
424GC |
BMC Cancer 2006 Mar 14;6:57 J Transl Med 2011 Aug 22;9:140
|
Myeloma |
Black 6 (B6NTac) |
|
|
5T33 |
Br. J. Cancer 1992 Dec;66(6):1088-93
|
Bladder Carcinoma |
Black 6 (B6NTac) |
|
|
MB49 |
J. Immunol. 1997 Jul 01;159(1):351-9
|
Hepatocellular carcinoma |
Black 6 (B6NTac) |
|
|
Hep-55.1C |
Hepatol. Res. 2016 Aug 08; Mol. Carcinog. 1992;6(2):148-58
|
Mammary Adenocarcinoma |
BALB/c |
|
+++ |
4T1 |
Breast Cancer Res. 2000;2(5):331-4 Nature 2015 May 07;521(7550):99-104 Carcinogenesis 2005 Mar;26(3):513-23 Clin. Exp. Metastasis 1999 Mar;17(2):163-70 Proc. Natl. Acad. Sci. U.S.A. 2007 Oct 02;104(40):15735-40
|
Mammary Adenocarcinoma |
BALB/c |
|
|
MC4-L3 |
Cancer Res. 2001 Jan 01;61(1):293-302
|
Colon Carcinoma |
BALB/c |
|
+++ |
CT26 |
Nat Commun 2017 Feb 21;8:14572 Cancer Res. 1980 Jul;40(7):2142-6 Proc. Natl. Acad. Sci. U.S.A. 2005 Jan 11;102(2):419-24 Cancer Res. 2013 Apr 15;73(8):2493-504 PLoS ONE 2016;11(9):e0161779 Carcinogenesis 2005 Mar;26(3):513-23
|
Prostate Adenocarcinoma |
Black 6 (B6NTac) |
|
|
TRAMP-C1A |
Cancer Res. 1997 Aug 15;57(16):3325-30 J. Biol. Chem. 2001 Apr 06;276(14):11204-13
|
Mammary Adenocarcinoma |
Black 6 (B6NTac) |
|
++ |
E0771 |
Cell Rep 2014 Mar 27;6(6):992-9 Dis Model Mech 2015 Mar;8(3):237-51 Proc. Soc. Exp. Biol. Med. 1951 Jun;77(2):358-62 Anticancer Res. 25(6B):3905-15 Nat Commun 2016 Jul 13;7:12258
|
Mammary Adenocarcinoma |
BALB/c |
|
|
MC4-L2 |
Cancer Res. 2001 Jan 01;61(1):293-302
|
Mammary Adenocarcinoma |
BALB/c |
|
++ |
D2A1 |
Carcinogenesis 2005 Mar;26(3):513-23 Clin. Exp. Metastasis 1993 Jan;11(1):103-12
|
Mammary Adenocarcinoma |
BALB/c |
|
|
MC4-L1 |
Cancer Res. 2001 Jan 01;61(1):293-302
|
Mammary Adenocarcinoma |
BALB/c |
|
+++ |
4T07 |
Int. J. Cancer 1991 Feb 01;47(3):466-72 Carcinogenesis 2005 Mar;26(3):513-23 Cancer Res. 1992 Mar 15;52(6):1399-405 Br. J. Cancer 1987 Nov;56(5):561-9
|
Squamous Cell Carcinoma |
C3H |
--- |
|
SCC-7 |
Cancer Lett. 2012 Apr 28;317(2):199-206 Cancer Res. 2016 Aug 15;76(16):4661-72 Br. J. Cancer 1982 Jul;46(1):109-16 Oncol Lett 2013 Dec;6(6):1799-1803
|
Lung Carcinoma |
BALB/c |
|
|
M109 (Madison Lung) |
In Vitro 1977 Apr;13(4):223-31 Cancer Treat Rep 1977 Nov;61(8):1459-70
|
Gastric Adenocarcinoma |
Black 6 (B6NTac) |
+ |
|
mGC3 |
BMC Cancer 2006 Mar 14;6:57 J Transl Med 2011 Aug 22;9:140
|
Mammary Adenocarcinoma |
DBA/1 |
|
|
dbrB |
Proc. Soc. Exp. Biol. Med. 80(4):696-7
|
Prostate Adenocarcinoma |
Black 6 (B6NTac) |
++ |
|
TRAMP-C1 |
Proc. Natl. Acad. Sci. U.S.A. 1997 Jul 22;94(15):8099-103 Cancer Res. 1997 Aug 15;57(16):3325-30
|
Acute Myeloid Leukemia |
Black 6 (B6NTac) |
|
|
C1498 |
J. Immunol. 1973 Jun;110(6):1470-5
|
Hepatocellular Carcinoma |
C3H |
- |
|
MH134 (MH134-TC) |
Cancer Immunol. Immunother. 1987;24(1):8-12 DNA Cell Biol. 2004 Sep;23(9):549-60 Cancer Res. 1985 Apr;45(4):1663-8
|
Fibrosarcoma |
Black 6 (B6NTac) |
|
|
MCA205 |
Cancer Immunol Res 2015 May;3(5):526-35 Neoplasia 2015 Aug;17(8):661-70 Oncoimmunology 2013 Jun 01;2(6):e24786
|
Lymphoma |
BALB/c |
|
|
PU5-1.8 (PU5-1R, TIB-61) |
J. Exp. Med. 1976 Jun 01;143(6):1528-33 Cancer Res. 1977 Feb;37(2):546-50
|
Colon Adenocarcinoma |
Black 6 (B6NTac) |
|
|
MC-38-CEA-2 |
Clin. Exp. Immunol. 2009 Jul;157(1):128-38 Cancer Res. 1991 Jul 15;51(14):3657-62
|
Mammary Adenocarcinoma |
Black 6 (B6NTac) |
|
|
Adenocarcinoma 755 (CA755) |
Int. J. Radiat. Oncol. Biol. Phys. 4(5-6):395-400 Oncotarget 2013 Oct;4(10):1829-35
|
Mammary Adenocarcinoma |
BALB/c |
|
|
MC4-L5 |
Cancer Res. 2001 Jan 01;61(1):293-302
|
Renal Adenocarcinoma |
BALB/c |
+ |
++ |
RenCa |
Cancer Res. 1986 Jul;46(7):3358-63 Carcinogenesis 2005 Mar;26(3):513-23 Mol. Ther. 2003 Apr;7(4):498-505 J. Immunol. 2006 Aug 15;177(4):2575-83
|
Mast Cell Leukemia |
DBA/2 |
++ |
|
P815 |
J. Immunol. 1984 Jun;132(6):3218-25 Curr Protoc Immunol 2001 May;Chapter 20:Unit 20.4 J. Immunol. 2006 Jul 01;177(1):162-8 Differentiation 1986;32(2):157-64
|
Pancreatic Adenocarcinoma |
Black 6 (B6NTac) |
|
++ |
Panc02 |
Clin Transl Sci 2008 Dec;1(3):228-39 Cancer Res. 1984 Feb;44(2):717-26 Eur Surg Res 2011;47(2):98-107 J. Immunother. 2010 Sep;33(7):697-705 J. Immunol. 2010 Oct 01;185(7):4063-71 J Vis Exp 2014 Sep 27;(91):51677 Int J Gastrointest Cancer 2001;29(1):37-46 Curr. Mol. Med. 2012 Mar;12(3):331-41
|
Leukemia |
BALB/c |
|
|
BCL1 |
Blood 2012 Jun 28;119(26):6344-53 Biol. Blood Marrow Transplant. 2014 Aug;20(8):1089-103
|
Colon Carcinoma |
BALB/c |
|
|
MC-26 (Colon 26, C-26) |
Cancer Res. 1975 Sep;35(9):2434-9 J. Nutr. 2005 Oct;135(10):2350-4 Proc. Natl. Acad. Sci. U.S.A. 2007 Jul 24;104(30):12457-61 Br. J. Cancer 2002 Aug 27;87(5):574-9
|
Mammary Adenocarcinoma |
C3H |
-- |
|
CaD2 |
Proc. Natl. Acad. Sci. U.S.A. 1977 Oct;74(10):4610-4 Cancer Lett. 1992 Jan 31;61(3):263-7
|
Pleiomorphic Cell Sarcoma |
Black 6 (B6NTac) |
- |
|
Lewis Sarcoma T241 |
Anticancer Res. 3(4):263-8 Cancer Res. 2011 Nov 01;71(21):6676-83
|
Plasmacytoma |
C3H |
+ |
|
X5563 |
Exp. Cell Res. 1970 Apr;60(1):61-77 Cancer Immunol. Immunother. 1987;24(1):8-12
|
Osteogenic Sarcoma |
C3H |
|
|
HE 10734 |
Cancer Chemother Rep 1964 Jan;34:11-7
|
Lymphocytic Leukemia |
DBA/2 |
|
|
P388 |
Leukemia 1999 Oct;13(10):1592-600
|
Plasmacytoma |
BALB/c |
|
|
ADJ/PC6 |
Anticancer Drugs 2005 Jul;16(6):653-7 Immunology 1982 Nov;47(3):503-10
|
Colorectal carcinoma |
BALB/c |
- |
|
51BLim10 |
Cancer Res. 1994 Dec 15;54(24):6477-83
|
Colon Adenocarcinoma |
BALB/c |
|
+++ |
LM17 |
Clin. Exp. Metastasis 1999;17(10):849-55
|
B cell Lymphoma |
C3H |
|
|
38C13 |
Adv Hematol 2012;2012:701704 Eur. J. Immunol. 1977 Jul;7(7):413-7 Haematologica 2006 Feb;91(2):176-83
|
Mammary Adenocarcinoma |
FVB |
- |
|
Tgl-1 |
Gene Ther. 2006 Oct;13(19):1391-402 Cancer Res. 1998 May 01;58(9):1965-71
|
Mesothelioma |
Black 6 (B6NTac) |
|
|
AE17 |
Oncol. Rep. 2012 Aug;28(2):707-13
|
Mammary Adenocarcinoma |
BALB/c |
|
+++ |
66C14 |
Breast Cancer Res. 2000;2(5):331-4 J. Cell. Biochem. 1988 Feb;36(2):129-36
|
Hepatocellular Carcinoma |
Black 6 (B6NTac) |
|
- |
Dt81Hepa1-6 |
PLoS ONE 2017;12(2):e0171215
|
Lymphosarcoma |
DBA/2 |
++ |
+++ |
MDW3 |
Int. J. Cancer 1989 May 15;43(5):828-36 J. Natl. Cancer Inst. 1981 Jan;66(1):129-39 Int. J. Cancer 1984 Nov 15;34(5):709-16
|
Lymphosarcoma |
DBA/2 |
-- |
+ |
MDAY-D2 |
Blood 2000 Jul 15;96(2):691-8 J. Cell Biol. 1995 Dec;131(6 Pt 2):1849-55 J. Natl. Cancer Inst. 1980 May;64(5):1221-30 Int. J. Cancer 1984 Nov 15;34(5):709-16
|
Prostate Adenocarcinoma |
Black 6 (B6NTac) |
- |
++ |
RM-1 |
Prostate 2009 Nov 01;69(15):1613-23 J. Steroid Biochem. Mol. Biol. 1995 May;52(5):403-13 Nat Commun 2013;4:1795
|
Prostate Adenocarcinoma |
Black 6 (B6NTac) |
|
|
TRAMP-C3 |
Cancer Res. 1997 Aug 15;57(16):3325-30
|
Hepatoma |
C3H |
|
|
Hepatoma 129 |
Cancer Res. 1987 Dec 01;47(23):6216-9
|
Melanoma |
Black 6 (B6NTac) |
-- |
++ |
B16 |
Clin. Cancer Res. 2007 Sep 15;13(18 Pt 1):5455-62 Cancer Lett. 1984 Aug;24(1):57-63 J. Natl. Cancer Inst. 1970 Oct;45(4):789-800 Carcinogenesis 2005 Mar;26(3):513-23 J. Cell Biol. 1969 Nov;43(2):263-74
|
Pancreatic Adenocarcinoma |
Black 6 (B6NTac) |
|
|
MT5 |
Gut 2016 Oct 21;
|
Squamous Cell Carcinoma |
Black 6 (B6NTac) |
|
++ |
mEERL |
J. Virol. 2008 Mar;82(5):2493-500 Oncotarget 2016 Apr 26;7(17):24194-207 Head Neck 2015 Mar;37(3):327-35 Arch. Otolaryngol. Head Neck Surg. 2007 May;133(5):495-502
|
Lung Adenocarcinoma (transformed with HPV16) |
Black 6 (B6NTac) |
-- |
++ |
TC-1 |
Nat. Med. 2016 Dec;22(12):1402-1410 Cancer Res. 1996 Jan 01;56(1):21-6 Proc. Natl. Acad. Sci. U.S.A. 2002 Dec 10;99(25):16232-6 Carcinogenesis 2005 Mar;26(3):513-23 Cancer Res. 2013 Apr 15;73(8):2493-504
|
Plasmacytoma |
BALB/c |
|
|
RPC5.4 |
Science 1971 Jan 08;171(3966):75-7
|
Mammary Carcinoma |
BALB/c |
|
|
EMT6 |
J. Natl. Cancer Inst. 1972 Sep;49(3):735-49
|